Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis; and LTG-418, a NaV1.8 inhibitor developed for the treatment of acute and chronic pain. Latigo Biotherapeutics, Inc. was formerly known as WVB-Desmond, Inc. and changed its name to Latigo Biotherapeutics, Inc. in March 2019. Latigo Biotherapeutics, Inc. was incorporated in 2018 and is based in Thousand Oaks, California.
Frequently asked questions
What sector does Latigo Biotherapeutics, Inc. Common Stock (LTGO) operate in?
Latigo Biotherapeutics, Inc. Common Stock belongs to the Other sector and operates in the Biotechnology industry.
What is Latigo Biotherapeutics, Inc. Common Stock (LTGO) current stock price?
As of the latest data, Latigo Biotherapeutics, Inc. Common Stock stock price is $15.21, with a previous close of $15.26. Latigo Biotherapeutics, Inc. Common Stock lost -$0.05 in the last trading session, representing a -0.33% loss.
What is Latigo Biotherapeutics, Inc. Common Stock (LTGO) current market capitalization?
Latigo Biotherapeutics, Inc. Common Stock market cap is approximately 1.01 billion.
What is Latigo Biotherapeutics, Inc. Common Stock (LTGO) Earnings Per Share (EPS)?
The trailing EPS is -$2.52, and the forward EPS is -$2.32.
What is Latigo Biotherapeutics, Inc. Common Stock (LTGO) EBITDA?
Latigo Biotherapeutics, Inc. Common Stock EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -25.49 million.
Does Latigo Biotherapeutics, Inc. Common Stock (LTGO) pay dividends?
No. Latigo Biotherapeutics, Inc. Common Stock does not pay a dividend.
When is Latigo Biotherapeutics, Inc. Common Stock (LTGO) next earnings report?
Latigo Biotherapeutics, Inc. Common Stock is expected to release its next earnings report on September 30, 2026.
What is Latigo Biotherapeutics, Inc. Common Stock (LTGO) beta (volatility) score?
Latigo Biotherapeutics, Inc. Common Stock has a beta of 0.012, indicating lower volatility than the overall market.
